Literature DB >> 1431591

Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.

W J McConathy1, J C Gesquiere, H Bass, A Tartar, J C Fruchart, C S Wang.   

Abstract

In this study we have examined effects of synthetic polypeptide fragments of apoC-III on the kinetic properties of lipoprotein lipase (LPL) activity. Based on the loss of 79% of LPL-inhibitory activity after CNBr cleavage at the N-terminal portion of apoC-III and a systematic search for synthetic peptides with LPL-inhibitory activity spanning the apoC-III sequence, we concluded that the N-terminal domain is the most important in the modulation of LPL activity. In addition, there are multiple attachment sites in apoC-III for its interaction with LPL and these sites reside in the hydrophilic sequences of apoC-III. Probably for this reason the intact apo-CIII exhibited higher inhibitory potential than its peptide components. Based on the deduced inhibition constants derived for the synthetic apoC-III1-79 we concluded that apoC-III is likely to exhibit a physiological role in regulating LPL activity since the derived dissociation constants for the LPL-apoC-III interaction are within the physiological concentration range of plasma apoC-III. In addition, as the synthetic apoC-III1-79 lacks the carbohydrate moiety, we also concluded that the presence of the oligosaccharide in native apoC-III is not essential for its inhibitory activity on LPL. The fact that the I50 (concentration for inhibition of LPL at 50% activity) decreases for apoC-III-1 when assayed in the presence of apoC-II indicated that the activator actually caused an increased affinity between LPL and apoC-III and demonstrated that apoC-III does not compete for the activator site of apoC-II.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1431591

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  37 in total

1.  The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.

Authors:  Stephanie M Fullerton; Anne V Buchanan; Vibhor A Sonpar; Scott L Taylor; Joshua D Smith; Christopher S Carlson; Veikko Salomaa; Jari H Stengård; Eric Boerwinkle; Andrew G Clark; Deborah A Nickerson; Kenneth M Weiss
Journal:  Hum Genet       Date:  2004-04-24       Impact factor: 4.132

2.  Impaired postprandial lipemic response in chronic kidney disease.

Authors:  Jeffrey M Saland; Lisa M Satlin; Jeanna Zalsos-Johnson; Serge Cremers; Henry N Ginsberg
Journal:  Kidney Int       Date:  2016-05-07       Impact factor: 10.612

Review 3.  Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Authors:  Werner J Geldenhuys; Li Lin; Altaf S Darvesh; Prabodh Sadana
Journal:  Drug Discov Today       Date:  2016-10-19       Impact factor: 7.851

4.  Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII.

Authors:  Yinyuan Ding; Yuhui Wang; Hong Zhu; Jianglin Fan; Liqing Yu; George Liu; Enqi Liu
Journal:  Transgenic Res       Date:  2010-12-01       Impact factor: 2.788

5.  Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations.

Authors:  Josephine Chiu; Kristin N Valente; Nicholas E Levy; Lie Min; Abraham M Lenhoff; Kelvin H Lee
Journal:  Biotechnol Bioeng       Date:  2016-12-27       Impact factor: 4.530

Review 6.  Omega-3 fatty acid supplementation and cardiovascular disease.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy
Journal:  J Lipid Res       Date:  2012-08-17       Impact factor: 5.922

7.  Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

8.  Synergistic effect between lipoprotein lipase and apolipoprotein C3 genes in determining the severity of coronary artery disease.

Authors:  Tarek A Abd-El-Aziz; Randa H Mohamed; Amal S El-Shal
Journal:  J Cardiovasc Transl Res       Date:  2013-02-02       Impact factor: 4.132

9.  Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Hu Zhou; Zhenghui G Jiang; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Daniel Figeys; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01-23       Impact factor: 5.922

10.  Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

Authors:  Eliete J B Bighetti; Patrícia R Patrício; Andrea C Casquero; Jairo A Berti; Helena C F Oliveira
Journal:  Lipids Health Dis       Date:  2009-11-23       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.